166 related articles for article (PubMed ID: 10195636)
1. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice.
Babai I; Samira S; Barenholz Y; Zakay-Rones Z; Kedar E
Vaccine; 1999 Mar; 17(9-10):1223-38. PubMed ID: 10195636
[TBL] [Abstract][Full Text] [Related]
2. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice.
Babai I; Samira S; Barenholz Y; Zakay-Rones Z; Kedar E
Vaccine; 1999 Mar; 17(9-10):1239-50. PubMed ID: 10195637
[TBL] [Abstract][Full Text] [Related]
3. A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains.
Babai I; Barenholz Y; Zakay-Rones Z; Greenbaum E; Samira S; Hayon I; Rochman M; Kedar E
Vaccine; 2001 Nov; 20(3-4):505-15. PubMed ID: 11672916
[TBL] [Abstract][Full Text] [Related]
4. Immunoadjuvant activity of interferon-gamma-liposomes co-administered with influenza vaccines.
van Slooten ML; Hayon I; Babai I; Zakay-Rones Z; Wagner E; Storm G; Kedar E
Biochim Biophys Acta; 2001 Mar; 1531(1-2):99-110. PubMed ID: 11278176
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of protection against influenza A virus by DNA vaccine encoding the hemagglutinin gene.
Operschall E; Pavlovic J; Nawrath M; Mölling K
Intervirology; 2000; 43(4-6):322-30. PubMed ID: 11251388
[TBL] [Abstract][Full Text] [Related]
6. Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase.
Yoshikawa T; Suzuki Y; Nomoto A; Sata T; Kurata T; Tamura Si
Vaccine; 2002 Nov; 21(1-2):60-6. PubMed ID: 12443663
[TBL] [Abstract][Full Text] [Related]
7. Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design.
Liu WC; Liu YY; Chen TH; Liu CC; Jan JT; Wu SC
Antiviral Res; 2016 Sep; 133():110-8. PubMed ID: 27491439
[TBL] [Abstract][Full Text] [Related]
8. Enhanced protection against viral infection by co-administration of plasmid DNA coding for viral antigen and cytokines in mice.
Operschall E; Schuh T; Heinzerling L; Pavlovic J; Moelling K
J Clin Virol; 1999 Jun; 13(1-2):17-27. PubMed ID: 10405888
[TBL] [Abstract][Full Text] [Related]
9. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
Brett IC; Johansson BE
Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults.
Ben-Yehuda A; Joseph A; Zeira E; Even-Chen S; Louria-Hayon I; Babai I; Zakay-Rones Z; Greenbaum E; Barenholz Y; Kedar E
J Med Virol; 2003 Apr; 69(4):560-7. PubMed ID: 12601765
[TBL] [Abstract][Full Text] [Related]
11. Fusing subunit antigens to interleukin-2 and encapsulating them in liposomes improves their antigenicity but not their protective efficacy.
Wales JR; Baird MA; Davies NM; Buchan GS
Vaccine; 2005 Mar; 23(17-18):2339-41. PubMed ID: 15755624
[TBL] [Abstract][Full Text] [Related]
12. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
13. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine.
Johansson BE
Vaccine; 1999 Apr; 17(15-16):2073-80. PubMed ID: 10217609
[TBL] [Abstract][Full Text] [Related]
14. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.
Wang D; Christopher ME; Nagata LP; Zabielski MA; Li H; Wong JP; Samuel J
J Clin Virol; 2004 Dec; 31 Suppl 1():S99-106. PubMed ID: 15567101
[TBL] [Abstract][Full Text] [Related]
15. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
[TBL] [Abstract][Full Text] [Related]
16. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines.
Joseph A; Louria-Hayon I; Plis-Finarov A; Zeira E; Zakay-Rones Z; Raz E; Hayashi T; Takabayashi K; Barenholz Y; Kedar E
Vaccine; 2002 Sep; 20(27-28):3342-54. PubMed ID: 12213404
[TBL] [Abstract][Full Text] [Related]
17. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge.
Galarza JM; Latham T; Cupo A
Viral Immunol; 2005; 18(1):244-51. PubMed ID: 15802970
[TBL] [Abstract][Full Text] [Related]
18. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge.
Galarza JM; Latham T; Cupo A
Viral Immunol; 2005; 18(2):365-72. PubMed ID: 16035948
[TBL] [Abstract][Full Text] [Related]
19. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs.
Chen Z; Matsuo K; Asanuma H; Takahashi H; Iwasaki T; Suzuki Y; Aizawa C; Kurata T; Tamura S
Vaccine; 1999 Feb; 17(7-8):653-9. PubMed ID: 10067670
[TBL] [Abstract][Full Text] [Related]
20. A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate.
Wodal W; Falkner FG; Kerschbaum A; Gaiswinkler C; Fritz R; Kiermayr S; Portsmouth D; Savidis-Dacho H; Coulibaly S; Piskernik C; Hohenadl C; Howard MK; Kistner O; Barrett PN; Kreil TR
Vaccine; 2012 Jun; 30(31):4625-31. PubMed ID: 22580355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
